Capricorn Fund Makes a Huge Bet on Nerve Repair With 687,000 Share Axogen (AXGN) Investment Worth $22.4 Million

1 month ago 21

Cory Renauer, The Motley Fool

Sun, April 26, 2026 astatine 9:58 AM CDT 4 min read

According to a recent SEC filing, Capricorn Fund Managers Ltd initiated a caller involvement successful Axogen (NASDAQ:AXGN) during the archetypal 4th of 2026. The money acquired 687,600 shares, with an estimated transaction worth of $22.36 cardinal utilizing quarterly mean pricing. As of March 31, 2026, the presumption was valued astatine $22.78 million, reflecting some the acquisition and consequent terms movements during the quarter.

This caller holding accounts for 3.55% of Capricorn Fund Managers Ltd’s reportable U.S. equity assets arsenic of March 31, 2026.
Top holdings aft the filing:
- NYSE:CVNA: $29.87 cardinal (4.7% of AUM)
- NYSE:BAC: $26.18 cardinal (4.1% of AUM)
- NASDAQ:ZYME: $25.22 cardinal (3.9% of AUM)
- NASDAQ:AXGN: $$22.78 cardinal (3.6% of AUM)
- NYSE:KKR: $19.61 cardinal (3.1% of AUM)
As of April 23, 2026, shares were priced astatine $37.41, up 139.5% implicit the past year, outperforming the S&P 500 by 107.3 percent points.

Metric

Value

Market capitalization	$2.04 billion
Revenue (TTM)	$225.21 million
Net income (TTM)	($15.70 million)
Price (as of marketplace adjacent April 24, 2026)	$39.25

Develops and markets surgical solutions for peripheral nervus repair, including Avance Nerve Graft, AxoGuard Nerve Connector, AxoGuard Nerve Protector, AxoGuard Nerve Cap, Avive Soft Tissue Membrane, and AxoTouch 2 constituent discriminator.
Generates gross chiefly done the merchantability of biologically derived grafts and aesculapian devices utilized successful nervus repair procedures, targeting some infirmary and outpatient surgical settings.
Serves hospitals, country centers, subject hospitals, and a scope of surgical specialists specified arsenic integrative reconstructive, orthopedic, hand, oral, and maxillofacial surgeons crossed the United States and prime planetary markets.

Axogen is simply a healthcare institution specializing successful precocious surgical solutions for peripheral nervus injuries. The institution leverages proprietary biologic and aesculapian instrumentality technologies to code captious gaps successful nervus repair, offering off-the-shelf and specialized products that trim surgical complexity and amended diligent outcomes. With a diversified merchandise portfolio and a focused commercialized strategy, Axogen maintains a competitory presumption successful the nervus repair conception of the aesculapian instrumentality industry.

Before speechmaking excessively overmuch into Capricorn’s abrupt involvement successful Axogen, it’s important to retrieve this institution has reported dependable losses, connected a GAAP basis, for implicit a decade.

Axogen was the 2nd largest caller concern Capricorn added to its portfolio successful the archetypal quarter. It besides plowed $29.9 cardinal into Carvana.

Read Entire Article